嘉事堂药业股份有限公司 独立董事工作制度 | | | | 第一章 | 总则 | | 1 | | --- | --- | --- | --- | | 第二章 | 任职资格 | | 2 | | 第三章 | 提名、选举、聘任 | | 3 | | 第四章 | 职责与履职方式 | | 5 | | 第五章 | 履职保障 | | 8 | | 第六章 | 附则 | 10 | | 2025 年 7 月 16 日 北京 经 2025 年第二次临时股东大会审议通过 第一章 总则 第一条 为进一步完善嘉事堂药业股份有限公司（以下简称公司） 的公司治理结构，促进公司规范运作，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司治理准则》《上市公司独立董事 管理办法》（以下简称"《独立董事管理办法》"）《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等法律法规、规范性文件及本公司《章程》 等有关规定，特制定公司独立董事工作制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，与公 司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独 ...

嘉事堂药业股份有限公司 股东会议事规则 2025 年 7 月 16 日 北京 经 2025 年第二次临时股东大会审议通过 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 股东会的召集 | 3 | | 第三章 | 股东会的提案与通知 | 5 | | 第四章 | 股东会的登记 | 7 | | 第五章 | 股东会的召开 | 8 | | 第六章 | 提案的审议 | 9 | | 第七章 | 股东会的表决 | 10 | | 第八章 | 股东会的会议记录及会议决议 | 12 | | 第九章 | 股东会决议的执行和信息披露 | 13 | | 第十章 | 附则 | 13 | 第一章 总则 第一条 为规范嘉事堂药业股份有限公司（以下简称"公司"） 行为，维护公司和股东的合法权益，明确股东会的职责和权限，保证 股东会规范、高效、平稳运作及依法行使职权，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股东会规则》、《深圳证券交易所股 票上市规则》以及《嘉事堂药业股份有限公司章程》（以下简称"《公 司章程》"）的有关规定 ...

2025 年 7 月 16 日 北京 经 2025 年第二次临时股东大会审议通过 嘉事堂药业股份有限公司 董事会议事规则 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 董事会与董事长的职权 1 | | 第三章 | 董事会会议制度 3 | | 第四章 | 董事会议事程序 4 | | 第五章 | 董事会会议的信息披露 7 | | 第六章 | 董事会决议案的执行和反馈 7 | | 第七章 | 附则 8 | 第一章 总则 第一条 为了确保嘉事堂药业股份有限公司（以下简称"公司"）董 事会落实股东会决议，确保董事会做出科学、迅速和谨慎的决策，规范董 事会的议事程序，根据《中华人民共和国公司法》等有关法律、行政法规、 部门规章和《嘉事堂药业股份有限公司章程》（以下简称"《公司章程》"）， 特制定本规则。 第二章 董事会与董事长的职权 第二条 根据《公司章程》的有关规定，董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的年度财务预算方案、决算方案； （五）制订公司的利润分配方案和弥补亏损方案； （六）制订 ...

嘉事堂药业股份有限公司公司章程 嘉事堂药业股份有限公司章程 2025 年 7 月 16 日 北京 经 2025 年第二次临时股东大会审议通过 | | | | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 6 | | 第四章 | 党委 7 | | 第五章 | 股东和股东会 8 | | 第一节 | 股东的一般规定 8 | | 第二节 | 控股股东和实际控制人 11 | | 第三节 | 股东会的一般规定 13 | | 第四节 | 股东会的召集 15 | | 第五节 | 股东会的提案与通知 17 | | 第六节 | 股东会的召开 19 | | 第七节 | 股东会的表决和决议 22 | | 第六章 | 董事和董事会 28 | | 第一节 | 董事的一般规定 28 | | 第二节 | 董事会 32 | | 第三节 | 独立董事 38 | | 第四节 | 董事会专门委员会 42 | | 第七章 | 审计委员会 43 | | 第八章 | 总裁及其他高级管理人员 45 | | 第九 ...

2. 本法律意见书制作过程中，承办律师已按照中国现行法律、法规的要求， 对与出具本法律意见书有关的文件资料进行了必要审查。 北京市安理律师事务所 关于嘉事堂药业股份有限公司 2025 年第二次临时股东大会的法律意见书 文件编号：安理法意（2025）嘉字第 071601 号 致：嘉事堂药业股份有限公司 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张善古律师、王瑞欣律师（以下 简称"承办律师"）担任嘉事堂药业股份有限公司于 2025 年 7 月 16 日召开的 2025 年第二次临时股东大会（以下简称"本次股东大会"）特别法律顾问，出席 会议，并出具本法律意见书。 本法律意见书系依据《中华人民共和国证券法》（以下简称"证券法"）、 《中华人民共和国公司法》（以下简称"公司法"）、中国证券监督管理委员会 《上市公司股东大会规则》（以下简称"股东大会规则"）、《深圳证券交易所 股票上市规则》等规范性文件及《嘉事堂药业股份有限公司章程》（以下简称"公 司章程"），并结合《嘉事堂药业股份有限公司第七届董事会第十六次临时会议 决议的公告》及《嘉事堂药业股份有 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-26 嘉事堂药业股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 1．本次股东大会未出现否决提案的情形。 2．本次股东大会未涉及变更以往股东大会已通过的决议。 特别提示： 一、会议召开和出席情况 （一）嘉事堂2025年第二次临时股东大会于2025年7月16日下午3点在公司二 楼会议室召开。会议由公司董事长徐曦先生主持，本次股东大会按照会议议程， 采用现场表决与网络投票相结合的表决方式，审议了相关议案并作出决议。本次 股东大会的召开符合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东出席的总体情况： 通过现场和网络投票的股东178人，代表股份120,441,068股，占公司有表决 权股份总数的41.2884％。 （1）通过现场投票的股东7人，代表股份117,649,375股，占公司有表决权 股份总数的40.3313％。 （2）通过网络投票的股东171人，代表股份2,791,693股，占公司有表决权 股份总数的0.9 ...

Group 1 - The company held its 16th temporary board meeting on June 30, 2025, with all 9 directors present and voting [1][2] - The board unanimously approved the proposal to amend the company's articles of association and related rules, which will be submitted for shareholder approval [1][2] - The company plans to revise the Independent Director Working System to align with legal requirements and business needs [2][3] Group 2 - The company has scheduled its second temporary shareholder meeting for July 16, 2025, in compliance with legal and regulatory requirements [3] - The decision to hold the shareholder meeting was also unanimously approved by the board [3]

Core Viewpoint - The company, Jiasitang Pharmaceutical Co., Ltd., has revised its Articles of Association to enhance corporate governance and compliance with regulatory requirements [1][2]. Summary by Relevant Sections Corporate Governance - The revision includes the addition of a section on independent directors to clarify their responsibilities and duties [1][2]. - A new chapter on the specialized committees of the board has been introduced to define their roles and responsibilities more clearly [1][2]. Terminology Adjustments - The term "shareholders' meeting" has been changed to "shareholders' assembly" throughout the document [1][2]. Compliance and Regulatory Updates - The revisions align with the Company Law of the People's Republic of China, the Guidelines for Articles of Association of Listed Companies, and the Shenzhen Stock Exchange Listing Rules [1][2]. - Outdated regulatory references have been removed from the Articles [1][2]. Operational Changes - The position of Chief Executive Officer has been removed, and the powers of the President have been refined [1][2]. - New provisions have been added regarding the reporting obligations if a shareholders' assembly cannot be held on time [2]. Future Actions - The proposed amendments will be submitted for approval at the second extraordinary general meeting of shareholders in 2025, after which the company will proceed with the necessary business registration procedures [2].

Core Viewpoint - 嘉事堂药业股份有限公司 is modifying its Independent Director Work System to align with updated legal regulations and business development needs, with the changes requiring approval at the upcoming shareholder meeting [1]. Summary by Sections Modifications to the Independent Director Work System - The company has proposed amendments to 11 articles of the Independent Director Work System [1]. - The specific details of the revisions are not listed in the announcement [1]. - The changes are in accordance with the Company Law (2023 Revision), the Guidelines for Listed Companies (2025 Revision), and the Shenzhen Stock Exchange Listing Rules [1]. Shareholder Involvement - Shareholders holding more than 1% of the company's issued shares can propose candidates for independent directors, subject to election by the shareholders' meeting [1]. - Nominators are prohibited from proposing candidates with whom they have a conflict of interest or other relationships that may affect the independent performance of duties [1]. - Investor protection agencies can publicly request shareholders to delegate their rights to nominate independent directors [1].

Core Points - The company is established as a joint-stock limited company in accordance with the Company Law of the People's Republic of China and other relevant regulations [4][6] - The registered capital of the company is RMB 291.707120 million [4] - The company was approved by the State-owned Assets Supervision and Administration Commission and registered in Beijing [4][6] - The company aims to utilize a sound operating mechanism to promote sustainable development and provide good returns to shareholders [6][7] Chapter Summaries Chapter 1: General Provisions - The company is established to protect the legal rights of shareholders, employees, and creditors [4] - The company was listed on the Shenzhen Stock Exchange on August 18, 2010, with an initial public offering of 40 million shares [4] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [5][6] Chapter 2: Business Objectives and Scope - The company's business objective is to promote the modernization and internationalization of the pharmaceutical industry in China [6] - The business scope includes the sale of various pharmaceutical products, medical devices, and food products [7] Chapter 3: Shares - The company issues shares in the form of stocks, with a par value of RMB 1.00 per share [8][9] - The total number of issued shares is 291.707120 million [8] Chapter 4: Party Committee - The company has established a Party Committee to ensure the implementation of national policies and oversee major decisions [14][15] Chapter 5: Shareholders and Shareholders' Meeting - The company maintains a shareholder register based on the records provided by the securities registration and settlement institution [16] - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][17] - The company must hold an annual shareholders' meeting within six months after the end of the fiscal year [25][50] Chapter 6: Shareholders' Meeting Procedures - The company must notify shareholders of meetings at least 20 days in advance for annual meetings and 15 days for temporary meetings [62][63] - The meeting must be presided over by the chairman or a designated representative [74] Chapter 7: Voting and Resolutions - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [82][84] - Ordinary resolutions require a simple majority, while special resolutions require two-thirds of the voting rights [82][84]